Ameliorative effects of 6‑gingerol in cerebral ischemia are mediated via the activation of antioxidant and anti‑inflammatory pathways

Biomed Rep. 2023 Feb 15;18(4):26. doi: 10.3892/br.2023.1608. eCollection 2023 Apr.

Abstract

Focal ischemia occurs when an embolus or thrombus occludes an artery, causing the rapid obstruction of cerebral blood flow. Although stroke represents a main cause of disability and mortality in developing countries, therapeutic approaches available for this condition remain very limited. The aim of the present study was to examine the effects of the phytochemical, 6-gingerol, on the brain infarct volume, neuronal loss and on the oxidative stress parameters, cyclooxygenase-2 (COX-2) and interleukin (IL)-6, in an animal model of focal ischemic stroke. Male Wistar rats, weighing 250-300 g, were divided into the following six groups: i) The control; ii) right middle cerebral artery occlusion (Rt.MCAO) + vehicle; iii) Rt.MCAO + piracetam; iv) Rt.MCAO + 6-gingerol (6-Gin) at 5 mg/kg body weight (BW); v) Rt.MCAO + 6-Gin at 10 mg/kg BW; and vi) the Rt.MCAO + 6-Gin at 20 mg/kg BW group. The rats in each group received the vehicle or piracetam or 6-gingerol intraperitoneally for 7 days following Rt.MCAO. The brain infarct volume, neuronal loss and alterations in antioxidant and anti-inflammatory levels were assessed in the cortex and hippocampus. The results revealed that the brain infarct volume, malondialdehyde level and the density ratio of COX-2 and IL-6 to β-actin were significantly decreased following treatment with 6-gingerol. In addition, neuronal density and superoxide dismutase activity in the cortex and hippocampus were increased. On the whole, the findings of the present study suggest that 6-gingerol exerts antioxidant and anti-inflammatory effects in vivo, which effectively ameliorate the brain damage induced by focal cerebral ischemic strok.

Keywords: 6-gingerol; anti-inflammatory; antioxidant; middle cerebral artery; stroke.

Grants and funding

Funding: The present study received funding from the Mahasarakham University Faculty of Medicine (Med MSU 2/65).